J&J(JNJ)

Search documents
Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again
ZACKS· 2025-07-03 17:11
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Johnson & Johnson (JNJ) . This company, which is in the Zacks Large Cap Pharmaceuticals industry, shows potential for another earnings beat.When looking at the last two reports, this world's biggest maker of health care products has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by ...
Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?
ZACKS· 2025-07-03 14:00
Core Viewpoint - Johnson & Johnson is currently under observation due to its stock performance and potential future direction, particularly in relation to earnings estimates and revenue growth [1][2]. Earnings Estimate Revisions - For the current quarter, Johnson & Johnson is expected to report earnings of $2.64 per share, reflecting a decrease of -6.4% year-over-year, with a slight increase of +0.5% in the Zacks Consensus Estimate over the last 30 days [5]. - The consensus earnings estimate for the current fiscal year is $10.62, indicating a growth of +6.4% from the previous year, with a minor adjustment of +0.1% in the last month [5]. - For the next fiscal year, the earnings estimate stands at $11, suggesting a growth of +3.6% compared to the prior year, with a recent increase of +0.2% [6]. - Johnson & Johnson holds a Zacks Rank 2 (Buy), indicating a favorable outlook based on earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $22.77 billion, representing a year-over-year increase of +1.4% [11]. - For the current fiscal year, the revenue estimates are $91.19 billion and $94.24 billion, indicating growth rates of +2.7% and +3.4%, respectively [11]. Last Reported Results and Surprise History - In the last reported quarter, Johnson & Johnson achieved revenues of $21.89 billion, a year-over-year increase of +2.4%, and an EPS of $2.77, up from $2.71 a year ago [12]. - The company exceeded the Zacks Consensus Estimate for revenues by +1.26% and for EPS by +7.78% [12]. - Johnson & Johnson has consistently beaten consensus EPS and revenue estimates over the past four quarters [13]. Valuation - Johnson & Johnson is graded B in the Zacks Value Style Score, indicating it is trading at a discount compared to its peers [17].
AI builds ideal dividend stock portfolio for H2 2025
Finbold· 2025-07-01 11:16
In the first six months of 2025, the stock market has been on a roller-coaster ride, hitting both lows and highs driven by trade tariff uncertainties and geopolitical tensions.Amidst this volatility, dividend stocks have offered a haven for investors seeking some cushion against market swings. Now, as the second half of the year begins, Finbold asked OpenAI’s ChatGPT to design a focused three-stock dividend portfolio blending stability, yield, and sector diversification.Johnson & Johnson (NYSE: JNJ) Johnson ...
全球及中国无菌容器系统动向追踪及前景动态分析报告2025-2031年
Sou Hu Cai Jing· 2025-07-01 04:16
【全新修订】:2025年7月 【出版机构】:中智信投研究网 【内容部分有删减·详细可参中智信投研究网出版完整信息!】 【免费售后 服务一年,具体内容及订购流程欢迎咨询客服人员 】 报告目录 全球及中国无菌容器系统动向追踪及前景动态分析报告2025-2031年 8 全球主要生产商简介 8.1 Rebstock Instruments 8.1.1 Rebstock Instruments基本信息、无菌容器系统生产基地、销售区域、竞争对手及市场地位 1 美国关税政策演进与无菌容器系统产业冲击 1.1 无菌容器系统产品定义 1.2 政策核心解析 1.3 研究背景与意义 1.3.1 美国关税政策的调整对全球供应链的影响 1.3.2 中国无菌容器系统企业国际化的紧迫性:国内市场竞争饱和与全球化机遇并存 1.4 研究目标与方法 1.4.1 分析政策影响 1.4.2 总结企业应对策略、提出未来规划建议 2 行业影响评估 2.1 美国关税政策背景下,未来几年全球无菌容器系统行业规模趋势 2.1.1 乐观情形-全球无菌容器系统发展形式及未来趋势 2.1.2 保守情形-全球无菌容器系统发展形式及未来趋势 2.1.3 悲观情形-全球 ...
Johnson & Johnson: Patience Will Be Rewarded
Seeking Alpha· 2025-06-30 15:13
Group 1 - The analysis of Johnson & Johnson (NYSE: JNJ) stock was last conducted on May 12, 2025, focusing on its resilience against tariff changes [1] - The investment style emphasized actionable and clear ideas derived from independent research [1] - The service offers in-depth articles weekly, targeting investors interested in similar investment strategies [1] Group 2 - The service claims to have assisted members in outperforming the S&P 500 while minimizing significant losses during periods of high volatility in both equity and bond markets [2] - A trial membership is available to evaluate the effectiveness of the proven investment method [2]
Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It.
The Motley Fool· 2025-06-27 08:12
Johnson & Johnson (JNJ -0.02%) is an iconic U.S. healthcare giant. It has changed over the years, but today its focus is on pharmaceuticals and medical devices. And it is an industry leader in both spaces. There are a lot of positives with J&J, as it is more commonly known on Wall Street, but there's one dark cloud that I can't ignore. And the shadow from that cloud is why I just can't justify buying Johnson & Johnson today.Why Johnson & Johnson is a great companyWhen I look for stocks, I generally start wi ...
J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?
ZACKS· 2025-06-26 14:41
Key Takeaways JNJ's MedTech sales rose 4.1% in Q1 2025, driven by new products and recent acquisitions. Headwinds in China from VBP and anticorruption efforts are expected to persist through 2025. Stronger second-half 2025 sales expected as comps ease and product momentum builds up across segments.Johnson & Johnson (JNJ) is one of the few large drug and medical device companies with a presence in both the pharmaceuticals as well as medical devices segments. J&J’s medical devices segment, called MedTech, o ...
解读全球制药企业50强榜单:中国创新药企距离“Big Pharma”还有多远
Mei Ri Jing Ji Xin Wen· 2025-06-26 12:07
Core Insights - The 2025 Global Pharmaceutical Companies Top 50 list has been released, with Johnson & Johnson's Innovative Medicines leading with $55.7 billion in sales, followed by AbbVie and Merck [1][2] - Novo Nordisk enters the top ten for the first time due to its GLP-1 drug semaglutide, while Merck rises from fourth to third place, driven by the strong performance of its drug Keytruda [1][3] - Six Chinese companies made the list, marking a significant increase, with BeiGene and Huadong Medicine making their debut [1][5] Group 1: Rankings and Sales Performance - The list is based on prescription drug sales, core product revenue, and R&D investment, reflecting significant changes in the pharmaceutical industry [2] - Merck's Keytruda has received FDA approval for 40 indications and is projected to generate $29.482 billion in sales in 2024, accounting for approximately 54.28% of Merck's prescription drug revenue [3] - Novartis dropped from third to seventh place, with a prescription drug sales forecast of $50.191 billion for 2024, facing challenges due to patent expirations [4] Group 2: Chinese Pharmaceutical Companies - Six Chinese companies ranked in the top 50, the highest number in five years, although all ranked below 30 due to smaller market sizes [5][6] - Chinese innovation in pharmaceuticals is gaining recognition, with significant presentations at major conferences like AACR and ASCO [5] - The future outlook for Chinese companies in the global pharmaceutical landscape appears promising, with expectations of increased rankings and numbers by 2030 [5] Group 3: Market Trends and Projections - The GLP-1 class of drugs is expected to dominate prescription drug sales, with projections indicating that Eli Lilly will become the top-selling pharmaceutical company by 2030 [4] - The ADC (antibody-drug conjugate) market is expanding, with significant transactions and research presentations from Chinese companies at international conferences [6] - The overall sentiment in the industry is improving, with a focus on the value of Chinese innovative drugs despite previous financing challenges [6]
Johnson & Johnson: Undervalued Dividend King With 65% Upside Potential
Seeking Alpha· 2025-06-24 15:49
When you think of long-term investments, companies that come to mind are usually the large, multi-national names, like Johnson & Johnson (NYSE: JNJ ) aka J&J . Although unexciting as an investment compared to, say, Bitcoin (Rick is a Wall Street Journal best-selling author with over 20 years of experience trading stocks and options. The most authoritative publications, including Good Morning America, Washington Post, Yahoo Finance, MSN, Business Insider, NBC, FOX, CBS, and ABC News, cover his work. His pass ...
J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications
ZACKS· 2025-06-23 14:15
Core Insights - Johnson & Johnson (J&J) received a positive recommendation from the EMA's CHMP for label expansions of its drugs Darzalex and Imbruvica for new indications [1][8] Group 1: Darzalex - The CHMP recommended expanding Darzalex's label to treat adults with high-risk smoldering multiple myeloma (SMM) [2][4] - If approved, Darzalex will be the first therapy for this patient population, which is currently managed through active monitoring [3] - The decision is supported by data from the phase III AQUILA study, showing significant reduction in the risk of progression or death compared to active monitoring [4] - Darzalex sales increased by 20% year over year to $3.24 billion in Q1 2025, driven by market share gains [5] Group 2: Imbruvica - The CHMP also recommended Imbruvica for treating adults with previously untreated mantle cell lymphoma (MCL) eligible for autologous stem cell transplant [9][10] - If approved, Imbruvica could be the first BTK inhibitor for this indication, potentially offering long remissions without the burden of transplant [10] - The recommendation is based on the TRIANGLE study, which demonstrated improved overall survival with Imbruvica plus chemotherapy [11] - J&J markets Imbruvica in partnership with AbbVie, sharing commercial responsibilities in the U.S. and international profits [12] Group 3: Stock Performance - J&J's stock has risen nearly 4% year to date, outperforming the industry, which has seen a 3% decline [6]